Discover how the novel compound KRM-II-81 is revolutionizing the treatment landscape for patients battling with pharmacoresistant epilepsy by targeting and suppressing epileptiform activity across cortical neural networks.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
KRM-II-81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy.
Smith et al., Heliyon 2024
DOI: 10.1016/j.heliyon.2023.e23752
Listen, we’ve got this incredible case, a young guy, 19, tough situation with seizures since he was a kid, right after a big tumor surgery. They’ve tried everything, but the seizures, they just wouldn’t stop. So, our team, the best team, they do this amazing work-up, video EEG, CT scans, the whole nine yards. And they find it, the problem area, right there in the left temporal lobe. We knew, we just knew he was perfect for seizure surgery.
So we go in, do this huge, successful frontotemporal craniotomy. We’re in there with the latest tech, electrocorticography, checking everything before and after we take out the bad part. And guess what? The seizures, they’re gone. The imaging, crystal clear, no more tumor. And this guy, he’s doing great, no seizures for a whole year, still on meds, but doing great.
And here’s the best part, we’re not just fixing him up, we’re advancing science. He says yes to using the tissue for research, and what do we find? This tissue, it’s still misbehaving outside the body, until we hit it with KRM-II-81. This stuff is groundbreaking, a real game-changer, not like your usual treatments. It calms the storms in the brain, and it’s got less baggage, side-effect wise. So we’re thinking, this could be the answer for all those tough cases out there. Really big stuff.